# Progress Note 03 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Jesse Owens (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML042-SYN
- Date: 2026-06-24
- Fictional facility: St. Posthumous Health Center
- Fictional author: Clarence Whitfield-Arroyo, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Day 1 of cycle 2 of nivolumab with carboplatin and pemetrexed. **S**

## History of present illness

Mr. Owens comes before his second cycle, three weeks after the first. He has not smoked since the morning of cycle 1. Varenicline gave him mild nausea for the first week, which settled by taking it after food; his dreams are vivid but not upsetting. After cycle 1 he was tired for four days and mildly nauseated for two, needing ondansetron twice. He has had no diarrhea, rash, cough beyond his usual, breathlessness, headache, or yellowing. He has been to five pulmonary rehabilitation sessions and walks most mornings. The hepatitis and HIV tests before cycle 1 were negative. He has had no thoughts of self-harm. **S**

| Element | Detail |
|---|---|
| Since the last visit | Cycle 1 three weeks ago; pulmonary rehabilitation started |
| Tobacco | Abstinent for three weeks on varenicline |
| Side effects | Fatigue for four days and mild nausea for two after cycle 1; no immune-related symptoms |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired for four days after cycle 1; weight 75.8 kg; no fever |
| Gastrointestinal | Positive | Mild nausea for two days after cycle 1 and in the first week of varenicline; no diarrhea |
| Respiratory | Negative | Morning cough less since stopping smoking; no breathlessness |
| Integumentary | Negative | No rash or itching |
| Endocrine | Negative | No heat or cold intolerance or unusual thirst |
| Neurological | Negative | No numbness or tingling; no headache |
| Psychiatric | Negative | Mood good; vivid dreams on varenicline; PHQ-2 0 |

7 systems reviewed. **S**

## Current medications

- Varenicline 1 mg oral tablet, one tablet by mouth twice daily after food, for 12 weeks and then a further 12 weeks to prevent relapse **S**
- Nivolumab 360 mg intravenous infusion over 30 minutes on day 1 of each 21-day cycle, for three cycles before surgery (one 240 mg and one 120 mg vial) **S**
- Carboplatin 10 mg/mL injection, 525 mg (AUC 5 by the Calvert formula, creatinine clearance 80 mL/min) intravenously on day 1 of each 21-day cycle, for three cycles **S**
- Pemetrexed 500 mg/m2 (970 mg for a body surface area of 1.94 m2) intravenously over 10 minutes on day 1 of each 21-day cycle, for three cycles **S**
- Folic acid 1 mg oral tablet, one tablet daily from one week before the first pemetrexed dose until three weeks after the last **S**
- Dexamethasone 4 mg oral tablet, one tablet twice daily on the day before, the day of and the day after each pemetrexed dose **S**
- Ondansetron 8 mg oral tablet, one tablet every 8 hours as needed for nausea during chemotherapy **S**

## Allergies

- No known allergy **S**

## Objective

BP 126/78 mmHg; pulse 74 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 96% on room air; weight 75.8 kg; BMI 23.9 kg/m². All vital signs are synthetic.

Hemoglobin: 13.6 g/dL; White cell count: 6.9 10*3/uL; Absolute neutrophil count: 4.1 10*3/uL; Platelets: 214 10*3/uL; Creatinine: 1 mg/dL; eGFR (CKD-EPI 2021): 84 mL/min/1.73 m²; Glucose: 101 mg/dL (high); ALT: 28 U/L; AST: 25 U/L; Total bilirubin: 0.5 mg/dL; TSH: 2.6 mIU/L; Free T4: 1.1 ng/dL; PHQ-2: 0. All results are synthetic.

## Change since baseline

- Hemoglobin: 15.1 g/dL at baseline, 13.6 g/dL at this visit **S**
- White cell count: 8.4 10*3/uL at baseline, 6.9 10*3/uL at this visit **S**
- Platelets: 262 10*3/uL at baseline, 214 10*3/uL at this visit **S**
- Creatinine: 1 mg/dL at baseline, 1 mg/dL at this visit **S**
- eGFR (CKD-EPI 2021): 84 mL/min/1.73 m² at baseline, 84 mL/min/1.73 m² at this visit **S**
- Glucose: 94 mg/dL at baseline, 101 mg/dL (high) at this visit **S**
- ALT: 22 U/L at baseline, 28 U/L at this visit **S**
- AST: 21 U/L at baseline, 25 U/L at this visit **S**
- Total bilirubin: 0.6 mg/dL at baseline, 0.5 mg/dL at this visit **S**
- PHQ-2: 1 at baseline, 0 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; weight 75.8 kg; blood pressure 126/78, pulse 74; oxygen saturation 96 percent |
| Mouth | No ulcers |
| Respiratory | Clear; no crackles |
| Skin | No rash |
| Neurological | Light touch and vibration normal in the feet |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Left upper lobe adenocarcinoma, stage IIB, on chemoimmunotherapy before surgery** (C34.12). Cycle 1 tolerated well; counts adequate (neutrophils 4.1, platelets 214), kidney and liver tests normal, thyroid normal. No immune-related adverse event. **S**
   - Cycle 2 today with the same doses.
   - Thoracic surgery review next week.
   - Restaging CT after cycle 3.
2. **Nicotine dependence, on varenicline** (F17.210). Three weeks abstinent; nausea settled with food. **S**
   - Continue varenicline 1 mg twice daily.
   - Quitline calls continue.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Blood count with neutrophils and platelets | Before each chemotherapy cycle | Completed today | Hemoglobin 13.6, white cells 6.9, neutrophils 4.1, platelets 214 |
| Laboratory | Immune-related adverse event laboratory panel: TSH, free T4, liver tests, creatinine and glucose | Before each immunotherapy infusion | Completed today | TSH 2.6, free T4 1.1; ALT 28, AST 25, bilirubin 0.5; creatinine 1.0, eGFR 84; glucose 101 non-fasting the morning after dexamethasone |
| Laboratory | Morning cortisol | Baseline and before each immunotherapy infusion (CMID); for symptoms | Deferred | Missed: the CMID schedule calls for cortisol before each infusion, but the cycle 2 order set did not include it and it was not drawn. No harm is expected: he has no fatigue beyond the days after chemotherapy, no low blood pressure, low sodium or dizziness. Corrective action: cortisol added to the standing order set for cycle 3 and to the blood tests before surgery |
| Examination | Immune-related adverse event symptom review (diarrhea, rash, cough, breathlessness, headache, jaundice) | Every visit on immunotherapy | Completed today | None |
| Examination | Peripheral neuropathy after platinum | Every visit during and after platinum therapy | Completed today | No symptoms; light touch and vibration normal |
| Self-management | Tobacco use and cessation treatment | Every visit | Completed today | Abstinent three weeks on varenicline |
| Survey | Distress and depression screening | Every visit; PHQ-9 and GAD-7 at diagnosis and at treatment transitions | Completed today | PHQ-2 0 |
| Examination | Dyspnea and cough assessment | Every visit | Completed today | Morning cough lighter since stopping smoking; no breathlessness |
| Self-management | Pulmonary rehabilitation (prehabilitation) | Before and after lung resection | Completed today | Five sessions attended |
| Imaging | Response imaging | After the three cycles before surgery | Due | Restaging CT after cycle 3 |

## Goal progress

- PET-CT, brain MRI, EBUS staging, tissue diagnosis, PD-L1 and comprehensive biomarker results and a tumor board plan within three weeks of the screening CT. Outcome by 2026-05-26: PET-CT in three days, brain MRI in four, EBUS in eight, tumor board in ten; PD-L1 and tissue sequencing back by the consultation, 15 days after the scan. **S**
- Stop smoking completely before treatment starts and stay stopped. In progress; target 2026-09-30. **S**
- Three cycles of chemoimmunotherapy before surgery without a delay of more than one week and without an immune-related adverse event of grade 2 or higher. In progress; target 2026-08-05. **S**
- Complete resection (R0) with systematic lymph node dissection within six weeks of the last cycle. In progress; target 2026-09-30. **S**
- Back to walking 3 km most mornings by three months after surgery. In progress; target 2026-09-30. **S**

## Guideline basis

- CMID: Clinical Monitoring Intelligence Database, lung cancer monograph (2026), Aether Forge
- NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer (2026), National Comprehensive Cancer Network
- Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol 2021;39(36):4073-4126 (PMID 34724392) (2021), American Society of Clinical Oncology
- Tobacco Smoking Cessation in Adults, Including Pregnant Persons: Interventions (2021), U.S. Preventive Services Task Force

## Follow-up

- Cycle 3 in three weeks. Thoracic surgery review next week. Visit with restaging CT after cycle 3. Call the oncology line for any warning sign. **S**
- Next scheduled visit 2026-08-05: after three cycles: restaging CT, decision for lobectomy, thyroid result and surgical preparation. **S**
